Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yaron Ehrlich

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Urologia Internationalis|October 3, 2024
Transformations in Benign Prostatic Hyperplasia Surgical Practices: A Longitudinal Study of Trends and PredictionsKarin Lifshitz, Ziv Savin, Tomer Bashi, et al.
Prostate International|December 31, 2025
Holmium laser enucleation of the prostate as a treatment option for patients with concurrent outlet obstruction and bladder diverticulumMichael Frumer, Iyad Khamaisi, Guy Levenberg, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Urologia Internationalis|October 3, 2024
Transformations in Benign Prostatic Hyperplasia Surgical Practices: A Longitudinal Study of Trends and PredictionsKarin Lifshitz, Ziv Savin, Tomer Bashi, et al.
Prostate International|December 31, 2025
Holmium laser enucleation of the prostate as a treatment option for patients with concurrent outlet obstruction and bladder diverticulumMichael Frumer, Iyad Khamaisi, Guy Levenberg, et al.
The Journal of Urology|August 26, 2021
Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm TrialK Kent Chevli, Neal D Shore, Andrew Trainer, et al.
Pageof 4